4.2 Article

Case control study: Serological evidence that Borrelia miyamotoi disease occurs nationwide in Japan

期刊

JOURNAL OF INFECTION AND CHEMOTHERAPY
卷 24, 期 10, 页码 828-833

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jiac.2018.06.017

关键词

Borrelia miyamotoi disease; Relapsing fever; Lyme disease; Borrelia; Tick-borne infectious disease; Glycerophosphodiester phosphodiesterase (GlpQ)

资金

  1. Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED)

向作者/读者索取更多资源

Since 2011, Borrelia miyamotoi disease (BMD) has been reported in five countries in the northern hemisphere. The causative agent of BMD is transmitted by Ixodes ticks, which are also vectors of Lyme disease borreliae. In this study, we examined 459 cases of clinically suspected Lyme disease (LD group), and found twelve cases that were seropositive for the glycerophosphodiester phosphodiesterase (GlpQ) antigen derived from B. miyamotoi. The retrospective surveillance revealed that the seroprevalence of anti-GlpQ in the LD group was significantly higher than in a healthy cohort. Seropositive cases were observed from spring through autumn when ticks are active, and the cases were geographically widespread, being found in Hokkaido-Tohoku, Kanto, Chubu, Kinki, and Kyushu-Okinawa regions. Seropositive cases for GlpQ were most frequent in the Chubu region (6.3%) where B. miyamotoi has been found in Ixodes ticks. Out of the twelve cases that were found in the LD group, three cases exhibited concomitant seropositivity to Lyme disease borreliae by western blot assay. This is the first report of serological surveillance for BMD in Japan, and we conclude that BMD occurs nationwide. (C) 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据